Company overview
Insilico Medicine offers AI-powered drug discovery platforms like Pharma.AI, PandaOmics for target identification, and Chemistry42 for novel molecule design to pharmaceutical companies. These tools enable end-to-end preclinical development, from target prioritization to Phase 1 readiness in 30 months, with licensing available. The company supports partnerships, including global R&D collaborations like with Eli Lilly, across fibrosis, cancer, immunology, and aging-related diseases, with 31 internal programs including 7 in clinical stages.
Insilico Medicine is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include insilico medicine, ai drug discovery, pharma.ai, target identification, generative chemistry.
Structured facts
- Website
- https://insilico.com/
- Markets served
- United States & Americas
- Keywords
- insilico medicine, ai drug discovery, pharma.ai, target identification, generative chemistry
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What AI platforms does Insilico Medicine provide for drug discovery?
- Insilico's Pharma.AI suite includes PandaOmics for target discovery and prioritization, Chemistry42 for generative molecule design, and Nach01 for multimodal molecular tasks like property prediction and retrosynthesis.
- What are Insilico's key therapeutic areas and pipeline status?
- Focus areas include fibrosis, cancer, immunology, and aging-related diseases, with a pipeline of 31 programs across 29 targets, including 7 in clinical stages and one in Phase 2 for idiopathic pulmonary fibrosis.
- Does Insilico offer licensing, partnerships, or global collaborations?
- Yes, they provide target discovery tools for licensing, pilot automated AI-driven partnering systems, and global R&D collaborations such as with Eli Lilly for multiple therapeutic areas.
Related editorial coverage
- Verge Rebrands AI Drug Discovery After Trial Setback
- AACR 2026: Myocarditis Risk, KRAS Inhibitors, mRNA Advances
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
